Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

[1]  M. Levy,et al.  Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma. , 2022, JCO precision oncology.

[2]  P. Kirchweger,et al.  Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies , 2022, World journal of clinical oncology.

[3]  J. Ptak,et al.  Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.

[4]  P. Albers,et al.  Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011. , 2022, European urology focus.

[5]  J. Schalken,et al.  Liquid biopsy in bladder cancer: state of the art and future perspectives. , 2022, Critical reviews in oncology/hematology.

[6]  D. Aust,et al.  The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). , 2021, Clinical colorectal cancer.

[7]  T. Powles,et al.  716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy , 2021, Annals of Oncology.

[8]  S. Pal,et al.  Learning from BISCAY: The future of biomarker-based trial design in bladder cancer. , 2021, Cancer cell.

[9]  T. Powles,et al.  ctDNA guiding adjuvant immunotherapy in urothelial carcinoma , 2021, Nature.

[10]  A. Ravaud,et al.  An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer , 2021, Nature Medicine.

[11]  J. Reis-Filho,et al.  Genomic profile of advanced breast cancer in circulating tumour DNA , 2021, Nature Communications.

[12]  B. Gyawali,et al.  Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. , 2021, European urology oncology.

[13]  T. Powles,et al.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[14]  A. Cimmino,et al.  Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer , 2021, Journal of personalized medicine.

[15]  A. Lenis,et al.  Bladder Cancer: A Review. , 2020, JAMA.

[16]  P. Pauwels,et al.  Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. , 2020, Cancer discovery.

[17]  A. Chaudhuri,et al.  Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. , 2020, JCO precision oncology.

[18]  G. Netto,et al.  Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer , 2020, Frontiers in Oncology.

[19]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[20]  X. Yi,et al.  Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer , 2020, Cell Death & Disease.

[21]  Lawrence C. LaPointe,et al.  Circulating epigenetic biomarkers for detection of recurrent colorectal cancer , 2020, Cancer.

[22]  J. Bellmunt,et al.  Erdafitinib for the treatment of metastatic bladder cancer , 2019, Expert review of clinical pharmacology.

[23]  Yuanyuan Zhou,et al.  Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. , 2019, Clinical chemistry.

[24]  Nam-Trung Nguyen,et al.  Advanced liquid biopsy technologies for circulating biomarker detection. , 2019, Journal of materials chemistry. B.

[25]  S. Pal,et al.  Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors , 2019, Therapeutic advances in medical oncology.

[26]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[27]  P. Jiang,et al.  Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. , 2019, Clinical chemistry.

[28]  C. Andersen,et al.  Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Ash A. Alizadeh,et al.  Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. , 2018, Cancer discovery.

[30]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. , 2018, European urology.

[31]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[32]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[33]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[34]  Marianne M. Casilla-Lennon,et al.  Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life , 2017, The Journal of urology.

[35]  K. Birkenkamp-Demtröder,et al.  Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. , 2019, The Journal of urology.

[36]  M. Nykter,et al.  Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer , 2017, Clinical Cancer Research.

[37]  N. Rosenfeld,et al.  Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer , 2017, Scientific Reports.

[38]  Davide Prandi,et al.  Clonal evolution of chemotherapy-resistant urothelial carcinoma , 2016, Nature Genetics.

[39]  T. Ørntoft,et al.  Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. , 2016, Cancer research.

[40]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[41]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[42]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[43]  T. Tammela,et al.  Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. , 2002, European urology.

[44]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.